Evidence map›Paper›PMID 41249826›Full record

ArticleNPJ vaccines2025

Replication in human cells supersedes serum antigenic match for the in vivo efficacy of an A/H1N1pdm09 LAIV virus.

Steffan Llewellyn, Katarzyna E Schewe, Sameer Ayaz, David Burbidge, Shaun Cooper, Jonathan Crowe, Sarah Dodd, Jemma Shapanis, Katie Tudor, Kathryn Ryan and 2 more

Abstract read
In one paragraph

Article in NPJ vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Steffan Llewellyn *Flu-BPD, Biopharmaceutical Development, R&D, AstraZeneca, Liverpool, UK.
Katarzyna E Schewe *Flu-BPD, Biopharmaceutical Development, R&D, AstraZeneca, Liverpool, UK.
Sameer AyazFlu-BPD, Biopharmaceutical Development, R&D, AstraZeneca, Liverpool, UK.
David BurbidgeFlu-BPD, Biopharmaceutical Development, R&D, AstraZeneca, Liverpool, UK.
Shaun CooperFlu-BPD, Biopharmaceutical Development, R&D, AstraZeneca, Liverpool, UK.
Jonathan CroweFlu-BPD, Biopharmaceutical Development, R&D, AstraZeneca, Liverpool, UK.
Sarah DoddFlu-BPD, Biopharmaceutical Development, R&D, AstraZeneca, Liverpool, UK.
Jemma ShapanisUK Health Security Agency, Porton Down, Salisbury, Wiltshire, UK.
Katie TudorFlu-BPD, Biopharmaceutical Development, R&D, AstraZeneca, Liverpool, UK.
Kathryn RyanUK Health Security Agency, Porton Down, Salisbury, Wiltshire, UK.
Lauren ParkerFlu-BPD, Biopharmaceutical Development, R&D, AstraZeneca, Liverpool, UK.
Oliver DibbenFlu-BPD, Biopharmaceutical Development, R&D, AstraZeneca, Liverpool, UK. oliver.dibben@astrazeneca.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

For FluMist®/Fluenz live attenuated influenza vaccine (LAIV), efficient virus replication in human nasal epithelial cells (hNEC) is an important factor in vaccine effectiveness (VE). The necessity of antigenic similarity of LAIV viruses to the WHO-recommended strains for VE is less clear. Here, we aimed to describe the relative importance of optimal hNEC replication and antigenic match in protection from wild-type (wt) challenge in vivo. The efficacy of an A/H1N1pdm09 LAIV strain (LAIV

Identifiers

PMID41249826
PMCPMC12623909

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.